Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Topline results from two pivotal phase III trials of SB-204 in patients with acne vulgaris

Jan. 30, 2017

Merck KGaA reports findings from phase Ib study of M-1095 in psoriasis

Jan. 26, 2017

FDA approves Rhofade, Allergan's topical treatment for persistent facial erythema

Jan. 20, 2017

FDA awards rare pediatric disease designation to TXA-127 from Tarix Orphan

Jan. 19, 2017

Promising results from final phase III trial of Cimzia in chronic plaque psoriasis

Jan. 19, 2017

Novel TyroSphere formulation of adapalene for topical acne therapy

Jan. 19, 2017

Sato Pharmaceutical obtains rights to SB-204 in Japan

Jan. 18, 2017

Valeant reports positive results from second phase III study of psoriasis drug

Jan. 11, 2017

FDA grants fast track status to FCX-007 from Fibrocell Science

Jan. 9, 2017

Dermira doses first patient in phase III acne study

Jan. 5, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.